A study to understand patient characteristics and treatment of stage III non-small-cell lung cancer patients

Not Applicable

Completed

• Conditions: Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lungHealth Condition 2: C348- Malignant neoplasm of overlappingsites of bronchus and lung

• Registration Number: CTRI/2018/10/016221
• Lead Sponsor: AstraZeneca Pharma India Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 494

Inclusion Criteria

1. Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations

2. Adult male or female (18 years old or according to age of majority as defined by local regulations)

3. First ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including small cell lung cancer [SCLC] and NSCLC) in the patientââ?¬•s medical records

4. Primary diagnosis of stage III NSCLC, confirmed by pathology, between 01 January 2013 and 31 December 2017

5. Available medical records at the participating site reflect at least 9 months of follow-up from the index date (unless patient died within the first 9 months of diagnosis)

Exclusion Criteria

1. Patients with a concomitant cancer at the time of diagnosis of stage III NSCLC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. A cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis

2. Patients initially diagnosed with stage I-II NSCLC who have progressed to stage III

Study & Design

• Study Type: Observational
• Study Design: Not specified